Cerdelga

Chemical Nameeliglustat
Dosage FormCapsule (oral; 84mg)
Drug ClassInhibitors
SystemBlood, Musculoskeletal
CompanySanofi-Aventis
Approval Year2014

Indication

  • For the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6v extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cerdelga (eliglustat) Prescribing Information2014Genzyme Ireland, Ltd., Waterford, Ireland.